We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Infant HIV Near Point-of-Care Test Field Evaluated

By LabMedica International staff writers
Posted on 30 Jan 2019
Perinatal human immunodeficiency virus (HIV) infection contributes to an increase in morbidity and mortality among children in their first years of life, and lack of antiretroviral treatment (ART) and late ART initiation has seen more than half of the infants infected with HIV die before their second birthday.

The first step in the provision of early infant diagnosis (EID) services and linkage to care among HIV exposed infants is early identification; however this still remains a challenge in sub-Saharan Africa (SSA). More...
Access to HIV diagnosis for HIV-exposed infants and children is a challenge in SSA because of the processes involved in HIV detection that require use of nucleic acid amplification tests conducted by trained personnel in centralized laboratories usually based in urban centers.

Scientists at the Kenya Medical Research Institute (Kisumu, Kenya) and their colleagues screened and evaluated 3,814 mother-infant pairs who presented to clinics and hospitals in a town in Kenya in 2016. In the six-month timespan of the study, there were 921 infants enrolled who were known to be exposed to HIV based on the mother's HIV status. Dried blood samples (DBS) samples were collected from HIV exposed children less than18 months of age enrolled in a cross-sectional study.

The team performed Rapid HIV testing using serial tests with Determine Rapid HIV-1/2 Antibody test followed if positive by Unigold Rapid HIV test kits. The team performed a field evaluation of GeneXpert HIV-1 Qual. The GeneXpert HIV-1 Qual Assay was performed on six different GeneXpert instruments by 10 trained laboratory technologists. The test was compared with the gold standard for EID PCR, COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative Test, v2.0 assay (CAP/CTM HIV-1) qualitative PCR.

The scientists performed a total of 969 POC tests on 921 (24.6%) children who were HIV exposed. Approximately 15% of the children were tested as newborns and 49% of them tested at routine EID visit of six weeks. Out of the 921 exposed infants identified throughout the study, 30 were found HIV positive through both the Roche CAP/CTM and near point of care (GeneXpert), leading to a mother-to-child transmission (MTCT) rate of 3.3%. A total of 969 results were correctly assayed, with a final sensitivity and specificity of 94.1% and 99.8%, respectively, with two false negative PCR found. The POC gave an error rate of 0.7%, (7/969 samples) and all were resolved after a repeat test.

The authors concluded that their study demonstrated that the GeneXpert POC EID assay has a high sensitivity and specificity and performs well in a field setting with high coverage of ART prophylaxis among mothers and children. The sensitivity and specificity of 94% and 99% respectively, does reflect the true performance of the device even though they had nine discordant results with Roche, seven were what Roche considered as “reference test” errors. The study was originally published on December 27, 2018, in the journal Public Library of Science ONE.

Related Links:
Kenya Medical Research Institute


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.